TFF Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 14, 2020
Company to hold conference call and webcast at
Management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at
Conference Call Details:
Domestic Dial-In Number: Toll-Free: (800) 816-3024
International Dial-In Number (857) 770-0106
Conference ID: 7287036
Webcast Registration Link: https://edge.media-server.com/mmc/p/rwrfx2up
Please access the Webcast Registration Link at least 15 minutes ahead of the Conference to register, download, and install any necessary audio software.
The conference call will also be available for replay for one month on the Company's website, https://tffpharma.com, in the Events Calendar of the Investors section.
About TFF Pharmaceuticals’ Thin Film Freezing technology platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
Chief Financial Officer
Investor Relations and Media Contact: